Compare GSBC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBC | GKOS |
|---|---|---|
| Founded | 1923 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.5M | 5.4B |
| IPO Year | N/A | 2015 |
| Metric | GSBC | GKOS |
|---|---|---|
| Price | $62.57 | $115.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $59.50 | ★ $126.38 |
| AVG Volume (30 Days) | 55.7K | ★ 735.2K |
| Earning Date | 01-20-2026 | 10-29-2025 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 18.31 | N/A |
| EPS | ★ 6.00 | N/A |
| Revenue | $228,683,000.00 | ★ $469,820,000.00 |
| Revenue This Year | N/A | $31.15 |
| Revenue Next Year | N/A | $24.15 |
| P/E Ratio | $10.47 | ★ N/A |
| Revenue Growth | 7.86 | ★ 30.38 |
| 52 Week Low | $47.58 | $73.16 |
| 52 Week High | $66.59 | $163.71 |
| Indicator | GSBC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 71.98 |
| Support Level | $65.08 | $115.07 |
| Resistance Level | $66.59 | $117.94 |
| Average True Range (ATR) | 1.27 | 2.91 |
| MACD | -0.35 | -0.13 |
| Stochastic Oscillator | 21.17 | 81.29 |
Great Southern Bancorp Inc is a bank holding company. It is principally engaged in the business of originating residential and commercial real estate loans, construction loans, commercial business loans, and consumer loans. The bank provides various services such as Business Banking, Merchant Services, Debit and Credit cards, Online Banking, Mobile Banking, VIP Banking, Overdraft Protection, and various other related services. It operates into a single segment which is Community Banking.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.